B. Riley Wealth Advisors Inc. Sells 51,067 Shares of Pfizer Inc. (NYSE:PFE)

B. Riley Wealth Advisors Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 249,606 shares of the biopharmaceutical company's stock after selling 51,067 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in Pfizer were worth $6,622,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at $28,000. Finally, Noble Wealth Management PBC purchased a new stake in Pfizer during the 4th quarter valued at $31,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded up $0.13 on Thursday, hitting $23.31. 14,096,536 shares of the company traded hands, compared to its average volume of 40,991,811. The company has a market capitalization of $132.50 billion, a price-to-earnings ratio of 16.53, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business's 50 day moving average price is $23.22 and its 200-day moving average price is $25.11. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.38%. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.